This recombinant monoclonal antibody is a research-grade biosimilar to BGB-A445, designed to target TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed on activated T cells that plays a crucial role in regulating immune responses by enhancing T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, TNFRSF4 promotes sustained T cell activation and memory formation, making it a critical checkpoint in adaptive immunity. Dysregulation of TNFRSF4 signaling has been implicated in autoimmune diseases, inflammatory conditions, and cancer, where it represents a promising immunotherapeutic target for modulating antitumor immunity.
BGB-A445 is an investigational agonistic antibody that activates TNFRSF4 signaling to enhance T cell-mediated immune responses against tumors. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF4 biology, exploring immune checkpoint modulation mechanisms, and evaluating combination immunotherapy strategies in preclinical cancer models and immune system studies.
Email: support@cusabio.com
Distributors Worldwide